Year-round

Human Factors Intern

Nemera

Nemera

1,001-5,000 employees

Designs, develops, manufactures drug delivery devices

Compensation Overview

$20 - $24/hr

Chicago, IL, USA

In Person

Some travel (~20%) required for usability study activities.

Category
UI/UX & Design (1)
Required Skills
Data Analysis
Requirements
  • Currently pursuing a bachelor's or master's degree in Human Factors, Cognitive Psychology, Industrial Engineering, or a related field
  • Currently a Junior or Senior (graduating 2027 or 2028)
  • Strong knowledge of human factors principles and methodologies
  • Familiarity with user-centered design processes and basic understanding of ergonomics
  • Excellent research and problem-solving skills
  • Strong technical writing and verbal communication abilities
  • Ability to work collaboratively in a team environment
  • Interest in human factors and product design for drug delivery/combination products
  • Relevant coursework or project experience is preferred
Responsibilities
  • Assist in planning and conducting usability studies
  • Analyze and interpret data collected from usability studies
  • Support the creation of research reports and presentations
  • Contribute to the development of user interface designs and prototypes
  • Collaborate with cross-functional teams to integrate human factors principles into product development processes
  • Some domestic travel (approximately 20%) will be required for supporting usability study activities

Nemera designs, develops, and manufactures drug delivery devices for pharmaceutical and biotech companies, spanning ophthalmic, nasal, buccal, parenteral, dermal, and inhalation routes. The devices are used to administer medicines and are developed and manufactured in collaboration with customers, often through co-development and customized production in a B2B model. It stands out by offering an end-to-end range of delivery solutions across multiple administration routes, supported by global manufacturing facilities and a wide distribution network. Its goal is to enable safer, more convenient self-administered therapies by providing scalable devices and related design and manufacturing services to partners.

Company Size

1,001-5,000

Company Stage

Acquired

Total Funding

$1.2B

Headquarters

La Verpillière, France

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Rising demand for diabetes and obesity injection pens drives La Verpillière expansion, starting production 2027.
  • New Szczecin hall strengthens leadership in GLP-1 drug market for obesity therapies.
  • Milfra acquisition in June 2021 expands footprint in Brazil's gynecology and urology markets.

What critics are saying

  • SteadyMed's Releev One captures Symbioze market share in GLP-1 delivery within 12-18 months.
  • Ypsomed's dose accuracy wins Novo Nordisk contracts, undercutting La Verpillière capacity in 6-12 months.
  • SHL Medical's DAI platform displaces Nemera's devices in Eli Lilly obesity pens within 12-24 months.

What makes Nemera unique

  • Nemera specializes in drug delivery devices across ophthalmic, nasal, buccal, parenteral, dermal, and inhalation routes.
  • Launched Symbioze wearable injector in October 2021 for self-administration needs.
  • Introduced UniSpray unidose nasal system for emergency systemic drug delivery.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Nemera who can refer or advise you

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-7%

1 year growth

-7%

2 year growth

-7%
Nemera
Jul 21st, 2025
Nemera expands production capacity in Szczecin to strengthen leadership in GLP-1 drug market

Nemera, a global leader in the design, development, and manufacturing of drug delivery device solutions, has inaugurated a new production hall at its state-of-the-art facility in Szczecin, Poland.

Nemera
Oct 11th, 2023
Nemera extends manufacturing capabilities in North America

That's the new space Nemera has acquired to set up the next state-of-the-art manufacturing facility.

Jobmatch Ohio
Sep 15th, 2023
Printer Operator- Off Shift

In May of 2014, Rexam sold the plastics business and the Berlin Plant was acquired by Nemera, naming the prescription products business as Centor Inc.

The Real Deal
Jul 25th, 2023
Panattoni gets $26M for Vernon Hills industrial building

French medical device manufacturer Nemera is expanding its industrial footprint in suburban Chicago.

Nemera
Mar 10th, 2023
Nemera reinforces commitment to sustainability with first integrated ESG report

Nemera France SAS is thrilled to announce the publication of its first integrated ESG report.